vs

Side-by-side financial comparison of FATE THERAPEUTICS INC (FATE) and INNSUITES HOSPITALITY TRUST (IHT). Click either name above to swap in a different company.

INNSUITES HOSPITALITY TRUST is the larger business by last-quarter revenue ($1.8M vs $1.4M, roughly 1.3× FATE THERAPEUTICS INC). On growth, INNSUITES HOSPITALITY TRUST posted the faster year-over-year revenue change (-1.1% vs -26.4%). Over the past eight quarters, INNSUITES HOSPITALITY TRUST's revenue compounded faster (2.1% CAGR vs -15.7%).

Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.

InnSuites Hospitality Trust, based in Phoenix, Arizona, is a real estate investment trust that invests in lodging. While it is formed as a real estate investment trust, it is not classified as a real estate investment trust for tax purposes. The company owns interests in two hotels, operates three hotels, provides management for three hotels, and licenses its InnSuites trademark for five hotels. The company's hotel ownership interests are a 51.01% interest in the Best Western InnSuites Tucson...

FATE vs IHT — Head-to-Head

Bigger by revenue
IHT
IHT
1.3× larger
IHT
$1.8M
$1.4M
FATE
Growing faster (revenue YoY)
IHT
IHT
+25.3% gap
IHT
-1.1%
-26.4%
FATE
Faster 2-yr revenue CAGR
IHT
IHT
Annualised
IHT
2.1%
-15.7%
FATE

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
FATE
FATE
IHT
IHT
Revenue
$1.4M
$1.8M
Net Profit
$-356.9K
Gross Margin
Operating Margin
-10.0%
Net Margin
-19.8%
Revenue YoY
-26.4%
-1.1%
Net Profit YoY
37.9%
-29.1%
EPS (diluted)
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FATE
FATE
IHT
IHT
Q4 25
$1.4M
$1.8M
Q3 25
$1.7M
$1.8M
Q2 25
$1.9M
$2.2M
Q1 25
$1.6M
$1.6M
Q4 24
$1.9M
$1.8M
Q3 24
$3.1M
$1.8M
Q2 24
$6.8M
$7.5M
Q1 24
$1.9M
$1.7M
Net Profit
FATE
FATE
IHT
IHT
Q4 25
$-356.9K
Q3 25
$-32.3M
$-391.2K
Q2 25
$-34.1M
$-121.0K
Q1 25
$-37.6M
$-595.2K
Q4 24
$-276.4K
Q3 24
$-47.7M
$-370.9K
Q2 24
$-38.4M
$-148.6K
Q1 24
$-48.0M
$-113.0K
Operating Margin
FATE
FATE
IHT
IHT
Q4 25
-10.0%
Q3 25
-1995.1%
-13.3%
Q2 25
-1938.5%
10.1%
Q1 25
-2534.1%
-30.9%
Q4 24
-7.1%
Q3 24
-1703.9%
-15.5%
Q2 24
-665.7%
2.4%
Q1 24
-2652.9%
-35.3%
Net Margin
FATE
FATE
IHT
IHT
Q4 25
-19.8%
Q3 25
-1852.4%
-21.7%
Q2 25
-1786.6%
-5.5%
Q1 25
-2309.5%
-36.4%
Q4 24
-15.1%
Q3 24
-1551.0%
-20.2%
Q2 24
-567.4%
-2.0%
Q1 24
-2493.7%
-6.5%
EPS (diluted)
FATE
FATE
IHT
IHT
Q4 25
$-0.04
Q3 25
$-0.27
$-0.04
Q2 25
$-0.29
$-0.01
Q1 25
$-0.32
$-0.07
Q4 24
$-0.03
Q3 24
$-0.40
$-0.04
Q2 24
$-0.33
$-0.02
Q1 24
$-0.47
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FATE
FATE
IHT
IHT
Cash + ST InvestmentsLiquidity on hand
$203.7M
Total DebtLower is stronger
$11.3M
Stockholders' EquityBook value
$207.2M
$3.6M
Total Assets
$318.9M
$13.9M
Debt / EquityLower = less leverage
3.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FATE
FATE
IHT
IHT
Q4 25
$203.7M
Q3 25
$215.4M
Q2 25
$222.8M
Q1 25
$240.4M
Q4 24
$279.1M
Q3 24
$296.9M
Q2 24
$304.9M
Q1 24
$121.3M
$1.3M
Total Debt
FATE
FATE
IHT
IHT
Q4 25
$11.3M
Q3 25
$11.2M
Q2 25
$10.5M
Q1 25
$10.7M
Q4 24
$10.3M
Q3 24
$10.0M
Q2 24
$9.7M
Q1 24
$9.7M
Stockholders' Equity
FATE
FATE
IHT
IHT
Q4 25
$207.2M
$3.6M
Q3 25
$234.1M
$4.0M
Q2 25
$261.4M
$4.4M
Q1 25
$288.4M
$4.6M
Q4 24
$318.7M
$5.2M
Q3 24
$362.3M
$5.5M
Q2 24
$397.0M
$6.0M
Q1 24
$426.1M
$6.2M
Total Assets
FATE
FATE
IHT
IHT
Q4 25
$318.9M
$13.9M
Q3 25
$343.7M
$14.2M
Q2 25
$371.6M
$14.0M
Q1 25
$398.7M
$14.2M
Q4 24
$440.7M
$15.0M
Q3 24
$495.0M
$15.1M
Q2 24
$528.8M
$15.3M
Q1 24
$569.9M
$15.7M
Debt / Equity
FATE
FATE
IHT
IHT
Q4 25
3.12×
Q3 25
2.82×
Q2 25
2.37×
Q1 25
2.34×
Q4 24
1.98×
Q3 24
1.81×
Q2 24
1.61×
Q1 24
1.58×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FATE
FATE
IHT
IHT
Operating Cash FlowLast quarter
$-106.1M
$-145.1K
Free Cash FlowOCF − Capex
$-112.0M
FCF MarginFCF / Revenue
-8183.9%
Capex IntensityCapex / Revenue
434.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-199.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FATE
FATE
IHT
IHT
Q4 25
$-106.1M
$-145.1K
Q3 25
$-24.4M
$-153.0K
Q2 25
$-24.6M
$279.8K
Q1 25
$-33.8M
$-1.1M
Q4 24
$-122.9M
$-146.7K
Q3 24
$-29.4M
$-44.6K
Q2 24
$-32.3M
$-459.4K
Q1 24
$-33.4M
$1.4M
Free Cash Flow
FATE
FATE
IHT
IHT
Q4 25
$-112.0M
Q3 25
$-26.6M
Q2 25
$-25.9M
Q1 25
$-35.0M
Q4 24
$-123.6M
Q3 24
$-29.9M
Q2 24
$-32.4M
Q1 24
$-33.4M
FCF Margin
FATE
FATE
IHT
IHT
Q4 25
-8183.9%
Q3 25
-1526.5%
Q2 25
-1360.7%
Q1 25
-2148.9%
Q4 24
-6645.4%
Q3 24
-973.1%
Q2 24
-477.8%
Q1 24
-1736.9%
Capex Intensity
FATE
FATE
IHT
IHT
Q4 25
434.8%
Q3 25
126.5%
Q2 25
71.4%
Q1 25
73.4%
Q4 24
39.2%
Q3 24
16.1%
Q2 24
0.8%
Q1 24
4.5%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FATE
FATE

Segment breakdown not available.

IHT
IHT

Room$1.7M96%
Other$74.1K4%

Related Comparisons